Nycomed completes $346M Bradley buy

3 March 2008

Danish drugmaker Nycomed has completed its previously-announced $346.0 million acquisition of US specialty and generics drugmaker Bradley Pharmaceuticals (Marketletter November 5, 2007). With this, Nycomed will expand the line of dermatological products currently offered through its PharmaDerm Division and thereby increase market coverage and drive future growth. Combined with Nycomed's Fougera Division, total annualized sales will be $450.0 million, making Nycomed a leader in the US dermatology market, the firm claims.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight